- Home
- MDAI vs ZURA Comparison
MDAI vs ZURA Comparison
Compare MDAI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- ZURA
- Stock Information
- Founded
- MDAI 2013
- ZURA 2022
- Country
- MDAI United States
- ZURA United States
- Employees
- MDAI N/A
- ZURA N/A
- Industry
- MDAI Medical/Dental Instruments
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDAI Health Care
- ZURA Health Care
- Exchange
- MDAI Nasdaq
- ZURA Nasdaq
- Market Cap
- MDAI 69.0M
- ZURA 69.9M
- IPO Year
- MDAI N/A
- ZURA N/A
- Fundamental
- Price
- MDAI $2.44
- ZURA $1.42
- Analyst Decision
- MDAI Strong Buy
- ZURA Buy
- Analyst Count
- MDAI 2
- ZURA 7
- Target Price
- MDAI $4.75
- ZURA $14.33
- AVG Volume (30 Days)
- MDAI 460.4K
- ZURA 873.4K
- Earning Date
- MDAI 08-12-2025
- ZURA 08-15-2025
- Dividend Yield
- MDAI N/A
- ZURA N/A
- EPS Growth
- MDAI N/A
- ZURA N/A
- EPS
- MDAI N/A
- ZURA N/A
- Revenue
- MDAI $29,962,000.00
- ZURA N/A
- Revenue This Year
- MDAI N/A
- ZURA N/A
- Revenue Next Year
- MDAI $15.15
- ZURA N/A
- P/E Ratio
- MDAI N/A
- ZURA N/A
- Revenue Growth
- MDAI 55.21
- ZURA N/A
- 52 Week Low
- MDAI $0.82
- ZURA $0.97
- 52 Week High
- MDAI $3.25
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- MDAI 49.07
- ZURA 48.03
- Support Level
- MDAI $2.34
- ZURA $1.44
- Resistance Level
- MDAI $2.55
- ZURA $1.61
- Average True Range (ATR)
- MDAI 0.17
- ZURA 0.12
- MACD
- MDAI -0.04
- ZURA -0.03
- Stochastic Oscillator
- MDAI 25.93
- ZURA 16.85
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.